AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments.
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSEABBV), saying it's “just a gem” and a “winner.” He added, “I can't believe the stock dropped so much.”
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Under the surface, markets remain preoccupied with the potential impact of tariffs, shifting inflation expectations, and the Federal Reserve’s policy trajectory.
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these spaces.
Pharmaceutical company AbbVie (NYSEABBV) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share was 4.3% below analysts’ consensus estimates.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.
Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings and positive macroeconomic data. The S&P 500 index stands at 6,118 points at midday trading in New York, not far from the all-time high of 6,128 points reached last Friday.
AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025.
AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue forecast of $31 billion for both drugs.
